By Lauren Berg ( July 6, 2023, 9:33 PM EDT) -- The U.S. Food and Drug Administration handed full approval to Eisai and Biogen's Alzheimer's treatment Leqembi on Thursday following a study that verified the drug's ability to slow cognitive decline in the early stages of the disease, a decision that opened the door for broader Medicare coverage of the treatment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.